Last reviewed · How we verify
NCT06898255
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
Phase 1 trial testing GFS202A injection in Cancer Cachexia in 36 participants. Currently enrolling.
8 June 2026
Quick facts
| Lead sponsor | Genfleet Therapeutics (Shanghai) Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 24 April 2025 |
| Primary completion | 8 June 2026 |
| Estimated completion | 6 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- GFS202A injection — full drug profile →
Conditions studied
- Cancer Cachexia — all drugs for Cancer Cachexia →
Sponsor
Genfleet Therapeutics (Shanghai) Inc. — full company profile →
Who can join
Adults 18 to 80, any sex, with Cancer Cachexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label, multi-center, phase I study to evaluate the safety/tolerability and pharmacokinetics of GFS202A in advanced solid tumor patients with pre-cachexia or cachexia. The primary objective is to assess the safety/tolerability of GFS202A, determine its maximum tolerated dose (MTD), and recommend a dose range for future studies. Enroll participants with cancer cachexia or precachexia to receive GFS202A monotherapy. During the study period, participants will undergo assessments for safety and preliminary efficacy according to the visit schedule. Pharmacokinetic, anti-drug antibody (ADA), and pharmacodynamic (PD) /biomarker samples will be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06898255
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Cachexia
Currently open trials in the same condition.
- NCT07237464 — To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Health · Phase 1 · recruiting
- NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
- NCT06868849 — A Study of JMT203 in Patients With Cancer Cachexia · Phase 1 · recruiting
- NCT05915325 — Physical Training for Elderly Cancer Patients With Cachexia · NA · active not recruiting
- NCT06780423 — Structural Characteristics of Trunk and Limb Muscles in Cachectic Colorectal Cancer Patients · recruiting
Other Genfleet Therapeutics (Shanghai) Inc. trials
Trials by the same sponsor.
- NCT07198321 — A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tum · Phase 1, PHASE2 · not yet recruiting
- NCT06500676 — A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations · Phase 1, PHASE2 · recruiting
- NCT06375733 — A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL · Phase 1, PHASE2 · recruiting
- NCT05934513 — A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Phase 1, PHASE2 · recruiting
- NCT05756153 — A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06898255 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genfleet Therapeutics (Shanghai) Inc.
- Last refreshed: 5 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898255.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing